EUVIMEDEUVIMED entdecken
Fall-Kontroll-StudieOpen Access · CC BY 4.0

PIVKA-II and hematological parameters in hepatocellular carcinoma and non-malignant chronic liver disease: A case-control biomarker comparison in a hepatitis-endemic population

Muhammad Sameer Hashmi iD, Muhammad Aqif Ilyas

PLOS One · 03.11.2026 · 21 (11) · e0361802

DOI: 10.1371/journal.pone.0361802 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift PLOS One, online erschienen am 03.11.2026. Verfasst von Muhammad Sameer Hashmi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Laboratory Technology, Faculty of Natural Sciences, University of Sindh, Jamshoro, Sindh, Pakistan. Hauptthemen laut MEDLINE: Prothrombin, Carcinoma, Hepatocellular, Biomarkers, Liver Neoplasms. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Early detection of hepatocellular carcinoma (HCC) remains challenging in hepatitis-endemic settings such as Pakistan, where surveillance commonly relies on ultrasonography and alpha-fetoprotein (AFP), both of which have limited sensitivity for early-stage disease. This study evaluated the diagnostic performance of serum Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II), complete blood count (CBC) parameters, and CBC-derived hematological indices for discriminating HCC from non-malignant chronic liver disease (CLD).

Methods

We conducted a case-control biomarker study involving 160 adults with CLD at Liaquat University Hospital, Sindh, Pakistan, between October 2025 and March 2026, including 74 patients with established HCC and 86 with non-malignant CLD. Serum PIVKA-II was measured using electrochemiluminescence immunoassay. CBC-derived neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, systemic immune-inflammation index, and red cell distribution width-to-platelet ratio were calculated. Between-group differences were assessed using non-parametric methods, and receiver operating characteristic (ROC) analysis evaluated discriminatory performance. Benjamini–Hochberg correction was applied to prespecified families of multiple comparisons.

Results

PIVKA-II demonstrated the strongest discriminatory performance, with an area under the ROC curve (AUC) of 0.753 (95% CI, 0.670–0.827). At a cutoff of >82.1 mAU/mL, sensitivity was 86.4% and specificity was 56.0%. Platelet count (AUC, 0.642) and the RDW-to-platelet ratio (AUC, 0.638) also demonstrated significant between-group differences that remained significant after false discovery rate correction, although their discriminatory performance was modest. PIVKA-II discrimination was substantially higher among patients with vascular invasion (AUC, 0.853) and advanced BCLC stage C/D disease (AUC, 0.853) than among those with early/intermediate BCLC A/B disease (AUC, 0.571). A combined model incorporating PIVKA-II, lymphocyte percentage, and platelet count yielded an AUC of 0.784, but did not significantly improve discrimination compared with PIVKA-II alone (p = 0.166). Bootstrap validation showed minimal optimism in the overall AUC; however, the optimal PIVKA-II cutoff demonstrated substantial variability, with a 95% percentile range of 58.7–715.8 mAU/mL. This was corroborated by an independent 10-fold cross-validation analysis, which yielded a comparable mean AUC of 0.751 for PIVKA-II (optimism = +0.002).

Conclusion

PIVKA-II demonstrated fair diagnostic discrimination between HCC and non-malignant CLD, with relatively high sensitivity but limited specificity. Its substantially lower performance in early/intermediate-stage disease and the marked instability of the optimal cutoff indicate that PIVKA-II should be considered a complementary biomarker rather than a standalone diagnostic test. Larger multicenter studies with standardized control populations and independent external validation are needed to establish robust population-specific thresholds and determine the incremental clinical value of combining PIVKA-II with hematological parameters.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProthrombinCarcinoma, HepatocellularBiomarkersLiver NeoplasmsProtein PrecursorsLiver DiseasesHepatitisHumansFemaleMaleCase-Control StudiesMiddle AgedROC CurveAdultBiomarkers, TumorPakistan

Substanzen

acarboxyprothrombinProthrombinBiomarkersProtein PrecursorsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Medical Laboratory Technology, Faculty of Natural Sciences, University of Sindh, Jamshoro, Sindh, Pakistan.
  • Department of Physiology, Faculty of Natural Sciences, University of Sindh, Jamshoro, Sindh, Pakistan.

ORCID-Profile: Muhammad Sameer Hashmi

Zitieren

APA

Hashmi, M. S., & Ilyas, M. A. (2026). PIVKA-II and hematological parameters in hepatocellular carcinoma and non-malignant chronic liver disease: A case-control biomarker comparison in a hepatitis-endemic population. PLOS One, 21(11), e0361802. https://doi.org/10.1371/journal.pone.0361802

Vancouver

Hashmi MS, Ilyas MA. PIVKA-II and hematological parameters in hepatocellular carcinoma and non-malignant chronic liver disease: A case-control biomarker comparison in a hepatitis-endemic population. PLOS One. 2026;21(11):e0361802. doi:10.1371/journal.pone.0361802

BibTeX
@article{Hashmi2026,
  author = {Hashmi, Muhammad Sameer and Ilyas, Muhammad Aqif},
  title = {PIVKA-II and hematological parameters in hepatocellular carcinoma and non-malignant chronic liver disease: A case-control biomarker comparison in a hepatitis-endemic population},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {11},
  pages = {e0361802},
  doi = {10.1371/journal.pone.0361802}
}
Kostenlos starten →